Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Myelin Swelling and Repair in CNS Demyelination
2026-08-14
Arafa and colleagues show that early CNS myelin damage is often marked by swelling rather than immediate sheath loss, and that some damaged sheaths can remodel or recover. Across zebrafish, rodent, and human tissue, the study identifies neuronal activity as a modifiable factor that can worsen or mitigate this early pathology.
-
Q-VD-OPh: Separating Caspase Death from Mitophagy
2026-08-13
Q-VD-OPh gives translational researchers a powerful way to distinguish caspase-dependent cell death from mitochondrial quality-control responses. By pairing this pan-caspase inhibitor with Rab14–Parkin mitophagy assays, investigators can build more rigorous models of neurodegeneration, apoptosis, and post-cryopreservation recovery.
-
Cy3 Goat Anti-Mouse IgG (H+L) Antibody Workflow
2026-08-13
Turn mouse primary-antibody binding into a bright, traceable Cy3 signal for immunofluorescence, western blotting, and flow cytometry. This workflow connects HMGB1 biomarker discovery with practical orthogonal validation while emphasizing controls, storage, and troubleshooting.
-
PD 173074: FGFR1/VEGFR2 Inhibition
2026-08-12
PD 173074 is an ATP-competitive FGFR1 tyrosine kinase inhibitor with reported nanomolar FGFR1 potency and measurable VEGFR2 inhibition. Its validated use in angiogenesis inhibition and cancer research is supported by structural, biochemical, cellular, and mouse-model evidence.
-
Ranolazine Workflows for Cardiac Ischemia
2026-08-12
Build reproducible Ranolazine experiments around late sodium current inhibition, calcium-load control, and metabolic remodeling. This guide connects cardiac ischemia research with carefully bounded liver-cell assays while separating established product properties from testable experimental hypotheses.
-
Rocilinostat (ACY-1215): Assay Guide
2026-08-11
A scenario-based guide to using Rocilinostat (ACY-1215), SKU A4083, in cell viability, proliferation, and cytotoxicity workflows. It connects HDAC6 selectivity, multiple myeloma combination studies, formulation control, and practical vendor-selection criteria.
-
L-Phenylephrine: α1A Signaling and Research Use
2026-08-11
L-Phenylephrine is an adrenergic α1A receptor agonist used to investigate vasoconstriction, cardiomyocyte stress responses, neural progenitor proliferation, and nasal airway physiology. Its α1A preference supports focused receptor studies, but product characterization and animal findings should not be treated as direct evidence of clinical efficacy or cardiac hypertrophy signaling.
-
Br-DAPI for Cardiac Lipotoxicity Assay Design
2026-08-10
Br-DAPI extends DNA quantification beyond routine nuclear imaging by providing a population-level readout for cardiac lipotoxicity studies. This article explains how the DAPI fluorescent dye can support live and fixed cell workflows while keeping ER-stress and apoptosis claims analytically separate.
-
Potassium Iodide: From Thyroid Biology to Translation
2026-08-09
Potassium Iodide is more than a conventional iodide source: it is a controllable research variable linking thyroid biology, assay design, and translational rigor. This thought-leadership article explains how KI supports thyroid-focused workflows, examines what a published MMP-2-responsive immunotherapy platform actually demonstrates, and defines where the connection is scientifically valid—and where it is not. The result is a practical framework for using a well-characterized reagent without overstating its role in oncology.
-
Wild and Cultivated Taihangia rupestris Bioactivity
2026-08-08
This 2026 RSC Advances study integrates UPLC-MS/MS, multivariate analysis, antioxidant assays, α-glucosidase inhibition, and activity-guided compound screening to compare wild and cultivated Taihangia rupestris leaves. Foothill cultivation produced the strongest chemical and functional profiles, supporting cultivation as a sustainable source of antioxidant and antidiabetic lead compounds while highlighting the contribution of flavonoids and phenolics.
-
Reversine Workflow for Aurora Kinase Studies
2026-08-07
Reversine provides a practical way to perturb Aurora kinase signaling across cancer-cell assays, mitotic imaging, and exploratory gastruloid screens. This workflow connects concentration planning and solvent control with the large-scale, single-structure phenotyping strategy reported in a 2025 gastruloid-array study.
-
Radioiodinated Balsalazide Disodium Enables Ulcerative Colit
2026-08-07
The reference study presents a robust protocol for radioiodinating balsalazide disodium, producing a stable and highly selective radiotracer for imaging ulcerative colitis (UC) in murine models. This innovation addresses key gaps in longitudinal in vivo tracking of colonic inflammation, with implications for preclinical IBD research and radiotracer workflow development.
-
DiscoveryProbe Protease Inhibitor Library in Applied Screeni
2026-08-06
The DiscoveryProbe™ Protease Inhibitor Library empowers researchers with 825 validated inhibitors for high-throughput screening, unlocking advanced protease activity modulation for disease pathway discovery and drug development. This article outlines actionable protocols, troubleshooting strategies, and best practices for maximizing data quality in apoptosis, cancer, and infectious disease research.
-
RAS Peptides and SARS-CoV-2: Angiotensin IV Enhances Viral E
2026-08-06
This study reveals that angiotensin IV, but not angiotensin II, modulates SARS-CoV-2 entry via the ACE2 receptor, highlighting a dual role for angiotensin IV in viral infectivity. The findings bridge cardiovascular peptide biology and virology, with implications for understanding COVID-19 susceptibility in the context of renin–angiotensin system dynamics.
-
VX-765: Potent Caspase-1 Inhibition for Advanced Inflammatio
2026-08-05
VX-765, a selective caspase-1 inhibitor, empowers researchers to dissect inflammasome-driven inflammation and pyroptosis with precision. Its robust in vitro and in vivo applications, coupled with troubleshooting flexibility, make it indispensable for cytokine modulation, barrier function, and cell death studies.